A detailed history of Lpl Financial LLC transactions in Cellectis S.A. stock. As of the latest transaction made, Lpl Financial LLC holds 81,347 shares of CLLS stock, worth $165,947. This represents 0.0% of its overall portfolio holdings.

Number of Shares
81,347
Previous 72,187 12.69%
Holding current value
$165,947
Previous $222,000 3.15%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$2.41 - $3.09 $22,075 - $28,304
9,160 Added 12.69%
81,347 $215,000
Q4 2023

Feb 14, 2024

BUY
$0.97 - $3.55 $8,274 - $30,281
8,530 Added 13.4%
72,187 $222,000
Q3 2023

Nov 13, 2023

BUY
$1.58 - $2.86 $78,447 - $141,999
49,650 Added 354.47%
63,657 $100,000
Q2 2023

Jul 31, 2023

BUY
$1.72 - $2.12 $2,838 - $3,498
1,650 Added 13.35%
14,007 $27,000
Q1 2023

May 10, 2023

BUY
$1.83 - $3.84 $22,613 - $47,450
12,357 New
12,357 $23,000
Q1 2021

May 14, 2021

SELL
$18.19 - $33.25 $295,605 - $540,345
-16,251 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$15.87 - $31.64 $257,903 - $514,181
16,251 New
16,251 $440,000

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $92.8M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Lpl Financial LLC Portfolio

Follow Lpl Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.